Rallis India SELL. Performance Highlights. `231 Target Price 189 CMP. 2QFY2018 Result Update Agrichemical. Investment Period 12 months

Similar documents
Rallis India NEUTRAL. Performance Highlights CMP. `237 Target Price - 1QFY2018 Result Update Agrichemical. Investment Period - 3-year price chart

Rallis India NEUTRAL. Performance Highlights CMP. `242 Target Price - 4QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart

Rallis India NEUTRAL. Performance Highlights CMP. `215 Target Price - 3QFY2017 Result Update Agrichemical. Investment Period - 3-year price chart

Amber Enterprises India Ltd

Parag Milk Foods BUY. Performance Update CMP. `256 Target Price `330. 2QFY2019 Result Update Dairy Products. Investment Period 12 Months

Garware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months

ITC ACCUMULATE. Performance Highlights CMP. `257 Target Price `284. 3QFY2017 Result Update FMCG. Investment Period 12 Months

Hindustan Media Ventures

Parag Milk Foods BUY. Performance Update CMP. `324 Target Price `410. 1QFY2019 Result Update Dairy Products. Investment Period 12 Months

Maruti Suzuki India BUY. Performance Update. CMP `9,315 Target Price `10,820. 1QFY2019 Result Update Automobile. Historical share price chart

Mahindra & Mahindra Ltd.

GMM Pfaudler Limited BUY. Performance Update CMP. `945 Target Price ` QFY2019 Result Update Industrial Machinery. Investment Period 12 Months

Asian Granito BUY. Performance Highlights CMP. `270 Target Price `351. Outlook and valuation. 3QFY2017 Result Update Ceramics

Bata India BUY. Performance Update. CMP Target Price `842. 1QFY2019 Result Update Footwear. Historical share price chart.

Coal India ACCUMULATE. Performance Highlights CMP. `338 Target Price `380. Outlook and valuation. 2QFY2016 Result Update Mining

Mahindra & Mahindra Ltd.

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 2QCY2017 Result Update Pharmaceutical. 3-year price chart.

Procter & Gamble Hygiene & Health Care

TV Today Network BUY. Performance Update CMP. `323 Target Price `498. 3QFY2019 Result Update Media. Investment Period 12 Months

Sanofi India NEUTRAL. Performance Highlights. CMP `4,301 Target Price - 4QCY2016 Result Update Pharmaceutical. Investment Period - 3-year price chart

Maruti Suzuki India BUY. Performance Update. CMP `6,705 Target Price `8,552. 2QFY2019 Result Update Automobile. Historical share price chart

Sanofi India NEUTRAL. Performance Highlights. CMP `4,007 Target Price - 3QCY2017 Result Update Pharmaceutical. Investment Period 12 months

Bata India BUY. Performance Update. CMP `1,008 Target Price `1,243. 2QFY2019 Result Update Footwear. Historical share price chart.

Blue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.

Greenply Industries BUY. The plywood maker for growing India. Target Price. Initiating Coverage Plywood. 3-year price chart.

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `495 Target Price - 4QFY2017 Result Update Pharmaceutical.

GAIL India NEUTRAL. Performance Highlights CMP. `363 Target Price - 2QFY2013 Result Update Oil & Gas. Investment Period -

Hero MotoCorp ACCUMULATE. Performance Highlights. CMP `3,226 Target Price `3,466. 3QFY2017 Result Update Automobile. 3-year price chart

TV Today Network BUY. Performance Update. CMP Target Price `315 `385. 2QFY2017 Result Update Media. Historical share price chart.

United Phosphorus REDUCE. Performance Highlights CMP. 1QFY2018 Result Update Agrichemical. Investment Period 12 months. 3-year price chart

Quick take. Ruchira Papers Ltd. BUY. Creating value through paper. Target Price. Investment Period 12 Months. 3 year daily price chart.

Music Broadcast BUY. Performance Update. CMP Target Price `329 `475. 2QFY2019 Result Update Media. Historical share price chart.

Inox Wind BUY. Performance Highlights. CMP Target Price `390 `505. 2QFY2016 Result Update Capital Goods. 3 year price chart

Ambuja Cements ACCUMULATE. Performance Highlights. CMP Target Price `207 `233. 3QCY2015 Result Update Cement. Quarterly results (Standalone)

Goodyear India BUY. Company Update. CMP Target Price `515 `631. Company Update Tyres. 3-year Daily Price Chart. Key Financials

Lupin BUY. Performance Highlights. CMP `1,493 Target Price `1,809. 2QFY2017 Result Update Pharmaceutical. 3-year price chart

Tata Steel NEUTRAL. Performance Highlights CMP. `226 Target Price - 2QFY2016 Result Update Steel. Investment Period - 3-year price chart

Music Broadcast BUY. Performance Update. CMP Target Price `293 `475. 3QFY2019 Result Update Media. Stock Info Sector Market Cap (Rs cr) Media

Sanofi India ACCUMULATE. Performance Highlights. CMP `4,410 Target Price `4,738. 1QCY2016 Result Update Pharmaceutical. 3-year price chart

Inox Wind BUY. Performance Highlights. CMP Target Price `242 `286. 4QFY2016 Result Update Capital Goods. 3 year price chart

Lupin 1QFY2018 Result Update

ACC BUY. Performance Highlights. CMP `1,397 Target Price `1,630. 3QCY2015 Result Update Cement

Amara Raja Batteries BUY. Performance Highlights. CMP `1,010 Target Price `1,167. 2QFY2017 Result Update Auto Ancillary. 3-year price chart

CCL Products BUY. Brewing Steadily. CMP Target Price `300 `360. Initiating Coverage Coffee. January 4, year price chart

Goodyear India ACCUMULATE. Performance Highlights. CMP Target Price `326 `374. 1QCY2012 Result Update Tyres. Key financials

United Phosphorus ACCUMULATE. Performance Highlights `754. CMP Target Price. 2QFY2018 Result Update Agrichemical. 3-year price chart

Cipla REDUCE. Performance Highlights. CMP Target Price `564 `490. 2QFY2017 Result Update Pharmaceutical. Investment Period - 3-Year Daily Price Chart

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `440 Target Price. 3QFY2017 Result Update Pharmaceutical. Investment Period -

Dr. Reddy s Laboratories

Cadila Healthcare NEUTRAL. Performance Highlights CMP. `390 Target Price - 2QFY2017 Result Update Pharmaceutical. Investment Period -

MRF BUY. Performance Highlights. CMP `9,407 Target Price `11,343. Company Update Automobile. Key financials

FY2017 FY2018E FY2019E

Mahindra & Mahindra Ltd.

Graphite India BUY. Performance Highlights CMP. `93 Target Price `124. 4QFY2012 Result Update Capital Goods. Investment Period 12 Months

Graphite India BUY. Performance Highlights. CMP Target Price `88 `109. 1QFY2012 Result Update Capital Goods

KEI Industries BUY. Performance Update. CMP Target Price `433 `508. 4QFY2018 Result Update Cable. Historical share price chart.

KEI Industries BUY. Performance Update. Target Price. 3QFY2018 Result Update Cable. Historical share price chart. Key Financials

Tata Consultancy Services (TCS)

Jindal Steel & Power BUY. CMP Target Price `200 `320. 1QFY2019 Result Update Steel & Power. Performance Update

Sun Pharma BUY. Performance Highlights. `783 Target Price `944 CMP. 1QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Quick take. VIP Industries BUY. Travelling smart on the luggage track. CMP Target Price `153 ` year daily price chart

Hero MotoCorp ACCUMULATE. Performance Highlights. CMP `3,718 Target Price `4,130. 1QFY2018 Result Update Automobile. 3-year price chart

Aurobindo Pharma ACCUMULATE. Performance Highlights. `780 Target Price CMP `855. 2QFY2019 Result Update Pharmaceutical. Investment Period 12 months

Aurobindo Pharma BUY. Performance Highlights CMP. `580 Target Price `823. 4QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Sun Pharma BUY. Performance Highlights. `683 Target Price `847 CMP. 2QFY2017 Result Update Pharmaceutical. Investment Period 12 months

Aurobindo Pharma BUY. Performance Highlights. `708 Target Price CMP `823. 2QFY2018 Result Update Pharmaceutical. Investment Period 12 months

GlaxoSmithKline Pharmaceuticals

LT Foods BUY. Performance Update. CMP Target Price `92 `128. 3QFY2018 Result Update Media February 12, 2018

Dr Reddy s Laboratories

Dr. Reddy s Laboratories

Cadila Healthcare ACCUMULATE. Performance Highlights. CMP 860 Target Price QFY2013 Result Update Pharmaceutical. Key financials (Consolidated)

LT Foods BUY. Performance Update. CMP Target Price `76 `128. 4QFY2018 Result Update Media

Tech Mahindra ACCUMLATE. Performance Highlights `495 `526. CMP Target Price. 2QFY2018 Result Update IT

Transport Corporation of India

Ambuja Cements NEUTRAL. Performance Highlights CMP. `155 Target Price - 1QCY2011 Result Update Cement. Investment Period - Key financials (Standalone)

SpiceJet BUY. Performance Highlights CMP. `32 Target Price `43. 1QFY2013 Result Update Airlines. Investment Period 12 Months.

ACC NEUTRAL. Performance Highlights. CMP `1,261 Target Price - 4QCY2012 Result Update Cement. Quarterly results (Standalone) Investment Period -

Ambuja Cements NEUTRAL. Performance Highlights CMP. `184 Target Price - 2QCY2012 Result Update Cement. Quarterly results (Standalone)

Cairn India ACCUMULATE. Performance Highlights. CMP Target Price `338 `382. 2QFY2013 Result Update Oil & Gas. Quarterly highlights (Consolidated)

Sun Pharma BUY. Performance Highlights. `739 Target Price `944 CMP. 4QFY2016 Result Update Pharmaceutical. Investment Period 12 months

Quick take. Ashok Leyland Ltd BUY. Scrappage policy to drive faster growth. Target Price. Investment Period 12 Months. 3-year price chart

TVS Motor Company BUY. Performance Highlights. CMP Target Price `39 `45. 2QFY2013 Result Update Automobile. Quarterly highlights (Standalone)

TV Today Network BUY. Go with the market leader. CMP Target Price `297 `363. Initiating Coverage Media. 3-year price chart

Aurobindo Pharma BUY. Performance Highlights CMP. `686 Target Price `877. 3QFY2017 Result Update Pharmaceutical. Investment Period 12 months

CCL Products BUY. Performance Update. CMP Target Price `278 `360. 3QFY2018 Result Update Coffee. Historical share price chart.

Century Plyboards Ltd

Blue Star Ltd BUY. Performance Update. CMP Target Price `754 `867. 4QFY2018 Result Update Cons. Durable. 3-year price chart.

Alembic BUY. Performance Highlights. Target Price. 1QFY2011 Result Update Pharmaceutical. Investment Period 12 months

Federal Bank BUY. Performance Highlights. Target Price. 1QFY2018 Result Update Banking. Stock Info Sector

Matrimony.com Ltd BUY. A complete package from matchmaking to wedding. Target Price. Initiating Coverage Internet Software & Services

ICICI Bank BUY. Performance Highlights. CMP Target Price `343 `460. Q3FY2019 Result Update Banking. 3-year price chart. Exhibit 1: Key Financials

ICICI Bank BUY. Performance Highlights. CMP Target Price `328 `416. 3QFY2018 Result Update Banking. 3-year price chart. Key financials (Standalone)

LIC Housing Finance BUY. Performance Highlights. CMP Target Price `532 `630. 3QFY2017 Result Update HFC. 3-Year Daily Price Chart

Maruti Suzuki ACCUMULATE. Performance Highlights. CMP `7,622 Target Price `8,501. 1QFY2018 Result Update Automobile

Ipca Laboratories ACCUMULATE. Performance Highlights. `533 Target Price CMP. 2QFY2018 Result Update Pharmaceutical. Investment Period 12 Months

Prakash Industries BUY. Performance Highlights. CMP Target Price `81 `124. 3QFY2011 Result Update Steel

HDFC Bank BUY. Performance Highlights. CMP `2,145 Target Price `2,500. Q3FY2019 Result Update Banking. 3-year price chart. Key financials (Standalone)

SUN TV Network NEUTRAL. Performance Highlights CMP. `297 Target Price - 1QFY2013 Result Update Media. Investment Period -

Simplex Infrastructures

Wipro ACCUMULATE. Performance Highlights CMP. `539 Target Price `582. 1QFY2017 Result Update IT. Investment Period 12 Months

Transcription:

Jan-12 Jun-12 Nov-12 Apr-13 Sep-13 Feb-14 Jul-14 Dec-14 May-15 Oct-15 Mar-16 Aug-16 Jan-17 Jun-17 Nov-17 2QFY2018 Result Update Agrichemical November 21, 2017 Rallis India Performance Highlights Y/E March (` cr) 2QFY2018 1QFY2018 % chg (qoq) 2QFY2017 % chg (yoy) Net sales 588 442 33.1 539 9.1 Other income 3 5 (26.2) 12 (72.1) Gross profit 354 205 72.2 210 68.4 Operating profit 122 69 76.5 96 27.6 Adj. Net profit 77 45 70.7 67 16.1 For 2QFY2018 Rallis India (Rallis) reported a yoy growth of 9.1% in sales to `588cr (v/s. `539cr in 2QFY2017). The performance of Rallis was impacted during the quarter on the back of transition to GST and high channel inventory. On the operating front, the OPM came in at 20.8% (v/s. 17.8% in 2QFY2017). Owing to lower sales growth the Adjusted Net profit grew by 16.1% yoy to `77cr (v/s. `67cr in 2QFY2017). We recommend a Sell. Decent performance; aided by OPM expansion: For 2QFY2018, the company reported a yoy growth of 9.1% in sales to `588cr (v/s. `539cr in 2QFY2017). The performance, was impacted during the quarter on back of transition to GST and high channel inventory. On the operating front, the gross margin came in at 39.8% (v/s. 39.0% in 2QFY2017), while marginally higher other expenses aided the OPM to come in at 20.8% (v/s. 17.8% in 2QFY2017). Owing to lower sales growth, the Adj. Net profit grew by 16.1% yoy to `67cr (v/s. `45cr in 1QFY2018). Outlook and valuation: For FY2017-19E, we expect a CAGR of 10.5% and 24.9% in net sales and profit respectively. At the current levels, the stock is trading at a fair valuation of 20.8x its FY2019E EPS. Hence, we downgrade our view from Neutral to Sell. SELL CMP `231 Target Price 189 Investment Period 12 months Stock Info Sector Agrichemical Market Cap (` cr) Net debt (` cr) 4,501 (212) Beta 52 Week High / Low Avg. Daily Volume 0.8 265/180 50,723 Face Value (`) BSE Sensex Nifty Reuters Code 1 33,478 10,327 RALL.BO Bloomberg Code RALI@IN Shareholding Pattern (%) Promoters 50.1 MF / Banks / Indian Fls 21.4 FII / NRIs / OCBs 3.6 Indian Public / Others 25.0 Abs. (%) 3m 1yr 3yr Sensex 7.0 29.9 18.2 Rallis India 2.0 26.8 3.3 Key financials (Consolidated) Y/E March (` cr) FY2016 FY2017 FY2018E FY2019E Net Sales 1,637 1,687 1,837 2,058 % chg (10.1) 3.0 8.9 12.1 Adj.Net Profit 143 139 180 216 % chg (9.0) (3.0) 29.6 20.3 EBITDA % 13.3 15.7 15.0 16.0 FDEPS (`) 7.4 7.1 9.2 11.1 P/E (x) 31.5 32.5 25.0 20.8 P/BV (x) 5.0 4.1 3.7 3.3 RoE (%) 16.7 13.8 15.5 16.9 RoACE (%) 19.2 20.1 18.4 20.1 EV/Sales (x) 2.7 2.5 2.3 2.0 EV/EBITDA (x) 20.7 15.7 15.1 12.7 ; Note: CMP as of November 21, 2017 3-year price chart 400 350 300 250 200 150 100 50 0 Sarabjit Kour Nangra +91-22-39357800 ext. 6806 sarabjit@angelbroking.com Please refer to important disclosures at the end of this report 1

(` cr) Rallis India 2QFY2018 Result Update Exhibit 1: 2QFY2018 performance (Consolidated) Y/E March (` cr) 2QFY2018 1QFY2018 % chg (QoQ) 2QFY2017 % chg (YoY) 1HFY2018 1HFY2017 % chg Net sales 588 442 33.1 539 9.1 1,030 985 4.5 Other income 3 5 (26.2) 4 (10.9) 8 178 (95.2) Total income 591 446 32.5 551 7.4 1,038 1,163 (10.8) Gross profit 234 205 14.0 210 11.5 440 412 6.7 Gross margin (%) 39.8 46.5 39.0 42.7 41.8 EBDITA 122 69 76.5 96 27.6 192 166 15.6 EBDITA margin (%) 20.8 15.7 17.8 18.6 16.9 Financial cost 1 1 (32.2) 1 (22.0) 2 3 (35.7) Depreciation 13 11 9.8 11 14.4 24 23 4.5 PBT 112 61 83.4 96 17.2 174 317 (45.2) Provision for taxation 35 16 29 21.5 51 76 (32.5) PAT Before Exc. And MI 77 45 70.7 67 16.1 123 241 (49.2) Minority 0 0 0 0 0 - Exceptional 0 0 0 0 120 Reported PAT 77 45 70.7 67 16.1 123 241 (49.1) Adjusted PAT 77 45 70.7 67 16.1 123 120 1.8 EPS (`) 4.0 2.3 3.4 6.3 6.2 Sales 9.1% yoy growth For 2QFY2018, the company s sales grew by 9.1% yoy to `588cr (v/s. `539cr in 2QFY2017). Management has indicated that though the transition to GST has been smooth, restocking has not been adequately executed. This is owing to a scanty monsoon and an extended dry spell during Aug-Sept 2017. During the quarter, Seeds business (Metahelix) reported de-growth of 13% yoy in revenue at `39.3cr. Operating efficiency narrowed the EBITDA loss at `4.4cr Vs. `5.5cr in 2QFY2017. Exhibit 2: Revenue performance 720 640 560 539 588 25 20 480 442 15 400 320 326 348 10 240 5 160 80 0 0 2QFY2017 3QFY2017 4QFY2017 1QFY2018 2QFY2018 (5) Total Revenue % YoY November 21, 2017 2

(` cr) (%) Rallis India 2QFY2018 Result Update OPM expands On the operating front, the gross margin came in at 39.8% (v/s. 39.0% in 2QFY2017). Thus, the OPM came in at 20.8% (v/s. 17.8% in 2QFY2017). The expansion in the OPM was mainly on back of the other expenses which rose by 1.1% yoy during the quarter. Exhibit 3: Margin trend (%) 50.0 46.5 46.1 40.0 39.0 39.6 39.8 30.0 20.0 10.0 17.8 15.7 12.0 15.6 20.8 0.0 2QFY2017 3QFY2017 4QFY2017 1QFY2018 2QFY2018 Gross margin EBITDA margin Earnings grow; driven by OPM expansion The Adj. Net profit grew by 16.1% yoy to `77cr (v/s. `67cr in 2QFY2017). The Reported Net Profit came in at `77cr v/s. `67cr, yoy growth of 16.1%, mainly driven by OPM expansion. Other income was `3.4cr in 2QFY2018 (v/s. 3.8cr 2QFY2017). Exhibit 4: Adjusted PAT trend 90 80 70 60 50 40 30 20 10 0 77 67 45 31 25 2QFY2017 3QFY2017 4QFY2017 1QFY2018 2QFY2018 35 30 25 20 15 10 5 0 (5) (10) (15) Adj PAT % YoY November 21, 2017 3

Investment arguments Company set to seize rising opportunities in the domestic crop protection market: India's overall pesticide consumption is one of the lowest in the world and has a huge potential to grow. We believe Rallis is well placed to seize this opportunity on the back of its wide distribution network, strong brands, and a robust new product pipeline. According to industry estimates, the unorganized market accounts for 50% of the industry. Nonetheless, we believe Rallis is in a position to wrest market share as well as charge a premium for its products. A lower base would result in 11.0% CAGR in the domestic business during FY2017-19E. Exports remain flat: Although a late entrant, the company has been enhancing its focus in the exports market, which is now turning out to be its main growth driver. Overall exports formed ~31% of sales in FY2017. In FY2017, the global weakness in the agrochemical industry had put pressure on Rallis exports business, which resulted in revenue coming in at `450cr. Moreover, going forward, the segment will continue to post a 15.0% CAGR over FY2017-19E. Seed business to augment the domestic portfolio: After the acquisition of Metahelix seeds business in 2010, the seeds business forms a major part of the domestic business of the company. During FY2017, Rallis seeds business (under Metahelix) reported a decent growth of 15% yoy to `280cr on the back of increased market share, and despite significant reduction in acreages for some of the key crops such as millet seeds and corn. The company is also strengthening its cotton portfolio and will be launching a new product to take on the market leaders in this crop. The management remains confident of Metahelix achieving 12-14% margin in a good monsoon year. Contract manufacturing ramping up slowly: Rallis plans to focus on contract manufacturing for exports and selectively target top players. To facilitate the same, the company has set up a plant at Dahej, which in FY2013 was working at full capacity and contributed significantly to the overall growth of the company. The company has bagged two CRAMS projects on a pilot basis during the year. The management expects to convert these pilot projects into full commercial contracts in FY2017 and contribute to earnings growth from FY2018-2019 onwards. Outlook and valuation Over FY2017-19E, we expect the company to post a CAGR of 10.5% and 24.9% in net sales and profit respectively. At the current level, the stock is trading at a fair valuation of 20.7x its FY2019E EPS. Hence, we are downgrading our view from Neutral to Sell. November 21, 2017 4

Jan-09 Jun-09 Nov-09 Apr-10 Sep-10 Feb-11 Jul-11 Dec-11 May-12 Oct-12 Mar-13 Aug-13 Jan-14 Jun-14 Nov-14 Apr-15 Sep-15 Feb-16 Jul-16 Dec-16 May-17 Oct-17 Share price (`) Rallis India 2QFY2018 Result Update Exhibit 5: Key assumptions Particulars (%) FY2018E FY2019E Domestic growth 11.0 11.0 Export growth 15.0 15.0 Total revenue growth 11.0 12.1 EBITDA margin 15.0 16.0 Capex (` cr) 70 70 Exhibit 6: P/E Band 450.0 400.0 350.0 300.0 250.0 200.0 150.0 100.0 50.0 0.0 Price 10x 15x 20x 25x 30x Exhibit 7: Peer valuation Company Reco Mcap CMP TP Upside P/E (x) EV/Sales (x) EV/EBITDA (x) RoE (%) CAGR (%) (` cr) (`) (`) (%) FY18E FY19E FY18E FY19E FY18E FY19E FY18E FY19E Sales PAT Rallis Sell 4,501 231 189 (18.3) 25.0 20.8 2.3 2.0 15.1 12.7 15.5 16.9 10.5 24.9 UPL Accumulate 44,006 754 805 7.0 20.7 16.9 2.5 2.1 13.7 11.4 22.8 23.4 15.0 12.2, Bloomberg Company background Rallis is one of the oldest and second largest pesticide agrichemical companies in the country with a market share of around 13% and belongs to the Tata Group. The company also has a credible presence in the international market. Contribution from the domestic business stands at ~70%, while exports account for the balance. November 21, 2017 5

Profit & loss (Consolidated) Y/E March (` cr) FY2014 FY2015 FY2016 FY2017 FY2018E FY2019E Gross sales 1,840 1,922 1,730 1,783 1,957 2,193 Less: Excise duty 114 121 119 105 130 144 Net Sales 1,726 1,801 1,612 1,678 1,828 2,049 Other operating income 21 21 26 9 9 9 Total operating income 1,747 1,822 1,637 1,687 1,837 2,058 % chg 19.8 4.3 (10.1) 3.0 8.9 12.1 Total Expenditure 1,485 1,545 1,398 1,415 1,554 1,722 Net Raw Materials 1,008 995 839 950 1,023 1,127.11 Other Mfg costs 344 343 406 319 347 389 Personnel 111 129 132 146 159 179 Other 23 23 21 23 24 27 EBITDA 240 256 214 263 274 327 % chg 20.8 6.5 (16.5) 23.2 3.9 19.7 (% of Net Sales) 13.9 14.2 13.3 15.7 15.0 16.0 Depreciation & Amort. 41 50 45 47 53 58 EBIT 221 228 195 225 230 279 % chg 18.9 3.1 (14.3) 15.2 2.4 21.3 (% of Net Sales) 12.8 12.6 12.1 13.4 12.6 13.6 Interest & other Charges 13 10 14 7 4 6 Other Income 6 4 4 4 4 4 (% of PBT) 3 2 2 2 2 2 Share in profit of Asso. Recurring PBT 214 222 186 222 230 277 % chg 26.3 3.4 (16.2) 19.3 4.0 20.3 Extraordinary Exp./(Inc.) - - - 158 - - PBT (reported) 214 222 186 63 230 277 Tax 62 62 39 83 51 61 (% of PBT) 28.8 27.9 21.0 131.2 22.0 22.0 Minority Interest 0.8 2.6 3.7 3.7 3.7 3.7 PAT (reported) 152 157 143 (20) 180 216 ADJ. PAT 152 157 143 139 180 216 % chg 32.9 3.5 (9.0) (3.0) 29.6 20.3 (% of Net Sales) 8.8 8.7 8.9 8.3 9.8 10.6 Basic EPS (`) 7.8 8.1 7.4 7.1 9.2 11.1 Fully Diluted EPS (`) 7.8 8.1 7.4 7.1 9.2 11.1 % chg 32.9 3.5 (9.0) (3.0) 29.6 20.3 November 21, 2017 6

Balance sheet (Consolidated) Y/E March (` cr) FY2014 FY2015 FY2016 FY2017 FY2018E FY2019E SOURCES OF FUNDS Equity Share Capital 19 19 19 19 19 19 Preference Capital - - - - - - Reserves & Surplus 699 795 880 1,092 1,194 1,332 Shareholders Funds 718 815 899 1,111 1,213 1,352 Minority Interest 10 10 4 0 0 0 Total Loans 75 111 75 37 37 80 Other Long Term Liabilities 4 4 4 - - - Long Term provisions 15 19 18 23 23 23 Deferred Tax Liability 32 36 39 26 26 26 Total Liabilities 853 993 1,038 1,198 1,300 1,482 APPLICATION OF FUNDS Gross Block 651 687 764 717 787 857 Less: Acc. Depreciation 233 282 327 374 427 484 Net Block 418 405 437 343 360 372 Capital Work-in-Progress 21 21 21 21 21 21 Goodwill 186 196 259 237 237 237 Investments 25 24 28 239 239 239 Long Term Loans and Adv. 98 110 110 137 137 137 Current Assets 549 680 650 728 748 1,028 Cash 9 7 8 10 28 26 Loans & Advances 40 28 35 324 65 269 Other 500 645 607 394 654 733 Current liabilities 445 443 467 507 442 553 Net Current Assets 104 237 183 221 306 475 Mis. Exp. not written off - - - - - - Total Assets 853 993 1,038 1,198 1,300 1,482 November 21, 2017 7

Cash flow statement (Consolidated) Y/E March (` cr) FY2014 FY2015 FY2016 FY2017 FY2018E FY2019E Profit before tax 214 222 186 63 230 277 Depreciation 41 50 45 47 53 58 (Inc)/Dec in Working Capital (7) (147) 55 (63) (66) (171) Direct taxes paid (62) (62) (39) (83) (51) (61) Cash Flow from Operations 186 63 246 (35) 166 102 (Inc.)/ Dec. in Fixed Assets (56) (36) (76) 47 (70) (70) (Inc.)/ Dec. in Investments (5) 1 (4) (211) - - Inc./ (Dec.) in loans and adv. Cash Flow from Investing (61) (35) (80) (164) (70) (70) Issue of Equity - - - - - - Inc./(Dec.) in loans (73) 40 (36) (33) - 43 Dividend Paid (Incl. Tax) (55) (68) (68) (78) (78) (78) Others (14) (1) - - (0) 0 Cash Flow from Financing (142) (29) (165) 202 (78) (34) Inc./(Dec.) in Cash (17) (2) 1 2 18 (2) Opening Cash balances 26 9 7 8 10 28 Closing Cash balances 9 7 8 10 28 26 November 21, 2017 8

Key ratios Y/E March FY2014 FY2015 FY2016 FY2017 FY2018E FY2019E Valuation Ratio (x) P/E (on FDEPS) 29.5 28.4 31.3 32.3 24.9 20.7 P/CEPS 23.2 21.6 23.8 162.1 19.2 16.3 P/BV 6.2 5.5 5.0 4.0 3.7 3.3 Dividend yield (%) 0.9 0.9 1.3 1.7 2.2 2.6 EV/Sales 2.6 2.5 2.7 2.5 2.3 2.0 EV/EBITDA 18.4 17.4 20.7 15.7 15.1 12.7 EV / Total Assets 5.2 4.5 4.3 3.5 3.2 2.8 Per Share Data (`) EPS (Basic) 7.8 8.1 7.4 7.1 9.2 11.1 EPS (fully diluted) 7.8 8.1 7.4 7.1 9.2 11.1 Cash EPS 9.9 10.6 9.6 1.4 11.9 14.1 DPS 2.0 2.0 3.0 4.0 5.0 6.0 Book Value 36.9 41.9 46.2 57.1 62.4 69.5 Dupont Analysis EBIT margin 12.8 12.6 12.1 13.4 12.6 13.6 Tax retention ratio 71.2 72.1 79.0 (31.2) 78.0 78.0 Asset turnover (x) 2.1 2.0 1.6 1.5 1.5 1.5 ROIC (Post-tax) 19.0 18.0 15.4 (6.3) 14.4 15.7 Cost of Debt (Post Tax) 8.7 7.9 11.6 (4.1) 7.8 7.8 Leverage (x) 0.2 0.2 0.2 0.1 0.0 0.0 Operating ROE 20.6 19.6 16.1 (6.5) 14.6 16.0 Returns (%) ROCE (Pre-tax) 26.4 24.7 19.2 20.1 18.4 20.1 Angel ROIC (Pre-tax) 35.9 32.4 25.7 26.7 23.7 25.2 ROE 22.7 20.5 16.7 13.8 15.5 16.9 Turnover ratios (x) Asset Turnover (Gross Block) 2.8 2.7 2.3 2.3 2.4 2.5 Inventory / Sales (days) 62 74 89 89 88 94 Receivables (days) 35 37 44 45 44 47 Payables (days) 98 105 119 126 111 105 WC cycle (ex-cash) (days) 20 33 46 42 49 65 Solvency ratios (x) Net debt to equity 0.1 0.2 0.1 0.0 0.0 0.1 Net debt to EBITDA 0.3 0.5 0.4 0.2 0.1 0.2 Interest Coverage (EBIT / Int.) 17.5 22.5 14.4 30.8 62.3 47.7 November 21, 2017 9

Research Team Tel: 022-39357800 E-mail: research@angelbroking.com Website: www.angelbroking.com DISCLAIMER Angel Broking Private Limited (hereinafter referred to as Angel ) is a registered Member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited and Metropolitan Stock Exchange Limited. It is also registered as a Depository Participant with CDSL and Portfolio Manager with SEBI. It also has registration with AMFI as a Mutual Fund Distributor. Angel Broking Private Limited is a registered entity with SEBI for Research Analyst in terms of SEBI (Research Analyst) Regulations, 2014 vide registration number INH000000164. Angel or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities Market. Angel or its associates/analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. This document is solely for the personal information of the recipient, and must not be singularly used as the basis of any investment decision. Nothing in this document should be construed as investment or financial advice. Each recipient of this document should make such investigations as they deem necessary to arrive at an independent evaluation of an investment in the securities of the companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Reports based on technical and derivative analysis center on studying charts of a stock's price movement, outstanding positions and trading volume, as opposed to focusing on a company's fundamentals and, as such, may not match with a report on a company's fundamentals. Investors are advised to refer the Fundamental and Technical Research Reports available on our website to evaluate the contrary view, if any. The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true, but we do not represent that it is accurate or complete and it should not be relied on as such, as this document is for general guidance only. Angel Broking Pvt. Limited or any of its affiliates/ group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Angel Broking Pvt. Limited has not independently verified all the information contained within this document. Accordingly, we cannot testify, nor make any representation or warranty, express or implied, to the accuracy, contents or data contained within this document. While Angel Broking Pvt. Limited endeavors to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. This document is being supplied to you solely for your information, and its contents, information or data may not be reproduced, redistributed or passed on, directly or indirectly. Neither Angel Broking Pvt. Limited, nor its directors, employees or affiliates shall be liable for any loss or damage that may arise from or in connection with the use of this information. Disclosure of Interest Statement Rallis India 1. Financial interest of research analyst or Angel or his Associate or his relative No 2. Ownership of 1% or more of the stock by research analyst or Angel or associates or relatives No 3. Served as an officer, director or employee of the company covered under Research No 4. Broking relationship with company covered under Research No November Ratings (Based 21, 2017 on expected returns Buy (> 15%) Accumulate (5% to 15%) Neutral (-5 to 5%) 10 over 12 months investment period): Reduce (-5% to -15%) Sell (< -15)